POSITIVE - Study (Part III) Heidelberg
Launched by GERMAN CANCER RESEARCH CENTER · Feb 4, 2014
Trial Information
Current as of June 07, 2025
Completed
Keywords
ClinConnect Summary
No description provided
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • NSCLC stage IIIB/IV
- • receiving systemic treatment (palliative radiotherapy accepted)
- • BMI \> 18
- • ECOG (Eastern Cooperative Oncology Group) performance status ≤ 2
- • signed informed consent
- Exclusion Criteria:
- • serious active infection (i.e. requiring an iv antibiotic, antifungal or antiviral agent)
- • inability to walk
- • immobility (more than two days)
- • previously untreated (non-irradiated or non-resected) symptomatic brain metastases;permitted are: (1) previously treated brain metastases \[radiotherapy, surgery, dexamethasone dosage 8 mg per day, anti-epileptic therapy\]; (2) asymptomatic brain metastases without additional therapy requirement
- • severe neurologic impairment (e.g. apoplectic insult, Morbus Parkinson, pareses of extremities)
- • severe cardiac impairment (e.g. cardiac insufficiency NYHA (New York Heart Association) \> III, myocardial infarction within the last three months, unexplained syncopal events, severe cardiac arrhythmias, high grade aortic stenosis)
- • severe respiratory insufficiency
- • uncontrolled pain
- • abuse of alcohol or drugs reducing compliance to the study
- • bone metastasis inducing skeletal fragility
- • any circumstance that would impede ability to give informed consent or adherence to study requirements.
About German Cancer Research Center
The German Cancer Research Center (DKFZ) is a leading biomedical research institution dedicated to advancing cancer research and its application in clinical settings. Located in Heidelberg, DKFZ conducts innovative studies aimed at understanding the complexities of cancer biology, developing novel therapeutic strategies, and improving patient outcomes. As a prominent clinical trial sponsor, the center collaborates with national and international partners to facilitate cutting-edge research, translating scientific discoveries into effective treatments. With a commitment to excellence and a multidisciplinary approach, DKFZ plays a pivotal role in the global fight against cancer.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Heidelberg, Baden Württemberg, Germany
Patients applied
Trial Officials
Michael Thomas, Prof. Dr.
Principal Investigator
Thoracic Oncology Clinic for Thoracic Diseases/University of Heidelberg
Joachim Wiskemann, Dr.
Principal Investigator
National Center for Tumor Diseases (NCT)
Simone Hummler, Dr.
Principal Investigator
Thoracic Oncology Clinic for Thoracic Diseases/University of Heidelberg
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials